For the estimated 750,000 Americans living with hypertrophic cardiomyopathy, the nonobstructive form has long represented a therapeutic dead end — no approved treatments exist despite causing substantial disability. A rigorous multi-domain responder analysis from the ACACIA-HCM trial now offers the clearest evidence yet that a targeted cardiac myosin inhibitor can simultaneously move multiple clinically meaningful markers in the right direction.
The ACACIA-HCM trial randomized 517 symptomatic patients with nonobstructive HCM (nHCM) to daily aficamten or placebo, with assessments at 36 weeks across five distinct endpoints: NYHA functional class or patient-reported global impression, peak oxygen uptake (VO₂, threshold ≥0.5 mL/kg/min improvement), left atrial volume index reduction (>10%), septal early diastolic mitral annular velocity improvement (e', >10%), and NT-proBNP reduction (≥50%). Patients were then stratified as nonresponders, limited, partial, or complete responders based on how many of the five endpoints they achieved. The aficamten arm demonstrated significantly higher rates of complete and partial response compared to placebo, with gains spanning both subjective symptom measures and objective hemodynamic and structural markers — a breadth of effect rarely seen in a single cardiac pharmacotherapy trial.
This responder framework deserves particular attention. Unlike single-endpoint trials that can be gamed by statistical thresholds, a five-domain composite responder analysis captures whether a drug meaningfully shifts the disease across its full pathophysiological footprint. Aficamten's mechanism — selective inhibition of cardiac myosin ATPase to reduce excess cross-bridge formation — addresses both hypercontractility and diastolic dysfunction, the twin drivers of nHCM morbidity. This positions it distinctly from mavacamten, which has approval only in obstructive HCM. The 36-week timeframe is adequate for functional endpoints but leaves open questions about long-term structural remodeling, arrhythmia burden, and mortality. The trial population, while globally recruited, skews toward symptomatic patients at referral centers, potentially limiting generalizability to milder or earlier-stage disease. Overall, this analysis is incrementally paradigm-shifting: it reframes nHCM as pharmacologically tractable and establishes a multi-domain responder methodology that could become a standard template for future HCM trials.